Dr. Reddy's Laboratories, Q2

Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Dr Reddy's Q2 performance sees revenue boost, but challenges persist
Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong 16.5 percent year-on-year rise, slightly exceeding the estimate of Rs 7,854 crore.
Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%
Dr Reddy's Lab’s average revenue will potentially increase 12 per cent Y-o-Y to Rs 7,734 crore as against Rs 6,902 crore in Q2FY24. On a quarterly basis, the revenues may rise by 0.4 per cent. The pharma company registered revenues of Rs 7,696 crore in the June quarter of FY25.
Dr Reddys Laboratories Q2 Results Live: Profit Falls by 15.28% YoY
Dr Reddys Laboratories Q2 Results Live : Dr Reddys Laboratories announced its Q2 results on November 5, 2024, revealing a mixed performance. The company's topline saw a significant increase of 16.45% year-over-year, yet profit fell by 15.28%, indicating challenges in maintaining profitability despite higher revenues.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
Business Insider4h
Dr. Reddy’s Reports Strong Q2FY25 Results and Strategic Expansions
Dr. Reddy’s Laboratories Ltd ( (RDY)) has released its Q2 earnings. Here is a breakdown of the information Dr. Reddy’s Laboratories Ltd presented to its investors. Dr. Reddy’s ...
ndtvprofit4h
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
Dr Reddy's Labs shares up 3% after Q2 results. What should investors do?
Healthcare major Dr Reddy's Labs shares rallied up to 3% to Rs 1,310 after its Q2 revenue rose 17% year-on-year (YoY) ...
Business Insider19h
Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by ...
ndtvprofit4h
Dr. Reddy’s Q2 Results Review - Performance Inline With Expectations; Upgrade To 'Hold': Systematix
The brokerage expects the new business avenues to take a few years before they start contributing profitably to the ...
Dr Reddy’s clocks 16.51% increase in Q2 revenues
New Delhi: Pharma major Dr Reddy’s Laboratories (DRL ... Its total operating expenses grew 34.3 per cent to Rs3,021.8 ...
cnbctv185h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Shares of Dr. Reddy's Laboratories Ltd. will be closely watched in Wednesday's trading as its revenue for the September ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
ndtvprofit1h
Dr Reddy's Share Price Rises As Analysts Upgrade Rating, Hike Target Price
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...